SIGA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SI

Mkt Cap

$228.1M

Volume

851.98K

Next Earnings

November 5th

Loading chart

SI

SIGASIGA Technologies Inc.

SIGA

Pay with—

Available Balance0.00

SI

Mkt Cap

$229.2M

Volume

851.98K

Next Earnings

November 5th

Chart Financials Earnings News About Dividends Insider Filings

SIGA (SIGA) Q1 2026 Earnings Call TranscriptSIGA Technologies reported Q1 2026 results with minimal product deliveries ($6M total revenue, $3M net loss) but highlighted strong forward momentum including a $13M Asia-Pacific oral TPOXX order expected in Q2, a new exclusive distribution agreement with Hikma for the Middle East and North Africa region, and ongoing development of pediatric and post-exposure prophylaxis formulations. The company maintains a strong balance sheet with $146M in cash and no debt, and paid a $0.60 special dividend per share.The Motley Fool · May 7, 2026

SIGA Declares Special Cash Dividend of $0.60 Per ShareSIGA Technologies announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. The dividend amount matches the special dividend declared in April 2025. CEO Diem Nguyen stated the announcement reflects the company's strong balance sheet and commitment to shareholder value while executing its strategy in global health and infectious disease prevention.Benzinga · Mar 26, 2026

ACTG Announces Publication of STOMP Results in the New England Journal of MedicineA major clinical trial (STOMP) published in the New England Journal of Medicine found that tecovirimat, an FDA-approved smallpox drug, did not improve mpox resolution in outpatient adults with clade II mpox. The randomized, placebo-controlled study of 412 participants showed 79% clinical resolution in the tecovirimat group versus 81% in the placebo group by day 29, with no significant differences in pain reduction or lesion healing.GlobeNewswire Inc. · Feb 25, 2026

Healthcare Is Sickly but These Dividend Yields up to 7% May Still Have a PulseHealthcare stocks have been stagnant since April, but offer attractive dividend yields ranging from 5.3% to 7.1%. The article highlights several healthcare REITs and pharmaceutical companies with high dividend potential despite market challenges.Investing.com · Aug 29, 2025

SIGA (SIGA) Q2 Revenue Soars 272%SIGA Technologies reported strong Q2 2025 financial performance, with revenue jumping 271.6% to $81.1 million, driven by major TPOXX antiviral therapy deliveries to U.S. government agencies. The company paid a special $0.60 per share dividend and maintained robust cash reserves.The Motley Fool · Aug 6, 2025

Sustainable Construction Materials Market to record $734.9 Bn by 2032, Says Global Market Insights Inc.The sustainable construction materials market is predicted to reach $734.9 billion by 2032, driven by the growing adoption of green certifications and standards. Companies are focusing on team training and understanding green benchmarks to strengthen their position in the evolving market. However, the adoption of sustainable materials faces challenges, including higher initial costs and varying standards across countries.GlobeNewswire Inc. · Jan 7, 2025

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens BermanSIGA Technologies, a biopharmaceutical company, is facing scrutiny over its disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox. The company's clinical trial for TPOXX® failed to meet its primary endpoint, leading to a significant drop in the stock price. SIGA also terminated its Chief Medical Officer, raising further concerns about the company's transparency.GlobeNewswire Inc. · Oct 7, 2024

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens BermanSIGA Technologies' lead product TPOXX failed to meet its primary endpoint in a clinical trial for Mpox treatment, leading to a significant drop in the company's stock price. The company also terminated its Chief Medical Officer, raising further concerns about transparency.GlobeNewswire Inc. · Oct 3, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of InvestorsSIGA Technologies, Inc. (SIGA) is under investigation by the Law Offices of Howard G. Smith due to potential violations of federal securities laws. The investigation is related to the termination of the company's Chief Medical Officer and the subsequent release of a video revealing concerns about the company's Monkeypox treatment.Benzinga · Oct 3, 2024

3 Promising Vaccine Stocks to Watch in the Event of an Mpox SurgeThe article discusses three pharmaceutical companies with potential to meet the demand for mpox vaccines: Bavarian Nordic, Emergent Biosolutions, and SIGA Technologies. It highlights their vaccine and treatment candidates, recent developments, and stock performance.Investing.com · Aug 19, 2024

to start trading

SI

SIGASIGA Technologies Inc.

SIGA

Pay with—

Available Balance0.00

Your PositionYou don't own any SIGA yet.

Related Tickers

Earnings

Dividends

Last · Apr 7

Amount$0.60

Yield18.93%

Annual$0.60